376,070 Shares in OraSure Technologies, Inc. (NASDAQ:OSUR) Bought by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA acquired a new stake in OraSure Technologies, Inc. (NASDAQ:OSUR) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 376,070 shares of the medical instruments supplier’s stock, valued at approximately $1,602,000.

Other large investors have also bought and sold shares of the company. Cannell Capital LLC increased its stake in shares of OraSure Technologies by 25.8% in the fourth quarter. Cannell Capital LLC now owns 3,549,050 shares of the medical instruments supplier’s stock valued at $29,102,000 after buying an additional 728,459 shares during the period. Acadian Asset Management LLC increased its position in OraSure Technologies by 38.1% during the 2nd quarter. Acadian Asset Management LLC now owns 2,195,582 shares of the medical instruments supplier’s stock valued at $9,349,000 after purchasing an additional 605,324 shares during the period. American Century Companies Inc. raised its holdings in OraSure Technologies by 30.1% during the 2nd quarter. American Century Companies Inc. now owns 1,809,897 shares of the medical instruments supplier’s stock worth $7,710,000 after purchasing an additional 418,603 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of OraSure Technologies by 8.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,906,687 shares of the medical instruments supplier’s stock worth $32,035,000 after purchasing an additional 301,558 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of OraSure Technologies by 135.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 492,477 shares of the medical instruments supplier’s stock valued at $3,029,000 after purchasing an additional 283,001 shares during the last quarter. 93.50% of the stock is owned by institutional investors.

OraSure Technologies Trading Down 0.5 %

NASDAQ:OSUR opened at $4.33 on Monday. OraSure Technologies, Inc. has a 12 month low of $3.91 and a 12 month high of $8.45. The stock has a market capitalization of $320.24 million, a price-to-earnings ratio of 14.43 and a beta of 0.05. The firm has a fifty day simple moving average of $4.33 and a two-hundred day simple moving average of $4.93.

OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.03 EPS for the quarter. The business had revenue of $54.34 million during the quarter, compared to analyst estimates of $53.35 million. OraSure Technologies had a return on equity of 9.15% and a net margin of 9.88%. Equities analysts predict that OraSure Technologies, Inc. will post -0.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

OSUR has been the topic of several recent analyst reports. StockNews.com lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Saturday, August 17th. Evercore ISI upped their target price on OraSure Technologies from $4.50 to $5.00 and gave the company an “in-line” rating in a research report on Wednesday, August 7th. Three investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, OraSure Technologies has an average rating of “Hold” and a consensus target price of $6.67.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.